AR056888A1 - Derivados de heterociclil imidazol - Google Patents
Derivados de heterociclil imidazolInfo
- Publication number
- AR056888A1 AR056888A1 ARP060105413A ARP060105413A AR056888A1 AR 056888 A1 AR056888 A1 AR 056888A1 AR P060105413 A ARP060105413 A AR P060105413A AR P060105413 A ARP060105413 A AR P060105413A AR 056888 A1 AR056888 A1 AR 056888A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- aryl
- unsubstituted
- heterocyclyl
- alkoxycarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de heterociclil imidazol, un proceso para prepararlos y con el uso de estos compuestos como medicamentos, especialmente como inhibidores de la aldosterona sintasa. Reivindicacion 1: Un compuesto de la formula general (1), en la cual (A) R1 es fenilo o piridilo si R, R2, R3 y R4 son hidrogeno y n es 0, por lo cual fenilo o piridilo está sustituido con 1-4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, aril-alcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, hidroxilo, trialquilsililo C1-4, trifluorometoxi o trifluorometilo, donde por lo menos un sustituyente está situado en la posicion ôparaö (con respecto al sistema de anillos 6,7-dihidro-5H-pirrolo[1,2-c]imidazol-7-ilo); o (B) R1 es fenilo o heterociclilo insaturado si R, R2, R3 y R4 son hidrogeno y n es 1, por lo cual el fenilo o heterociclilo insaturado está sustituido con 3-4 alcoxi C1-8, alcoxicarbonilo C1- 8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, aril-alcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, trialquilsililo C1-4, trifluorometoxi o trifluorometilo; o (C) R1 es arilo o heterociclilo insaturado, radicales que están sustituidos con 1-4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfanilo C1-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, arilalcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, hidroxilo, nitro, oxido, oxo, trialquilsililo C1-4, trifluorometoxi o trifluorometilo, donde por lo menos un sustituyente es alquilsulfanilo C1-8, hidroxilo, nitro u oxido; o (D) R1 es arilo o heterociclilo insaturado si R3 y R4 no son simultáneamente deuterio o hidrogeno, por lo cual arilo o heterociclilo insaturado está sustituido con 1-4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, aril-alcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, oxo, trialquilsililo C1-4, trifluorometoxi o trifluorometilo; o (E) R1 es arilo o heterociclilo insaturado si R2 es hidroxilo o alcoxi C1-8, donde el arilo o heterociclilo insaturado está sustituido con 1-4 alcoxi C1-8, alcoxicarbonilo C1-8, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, aril-alcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, oxo, trialquilsililo C1-4, trifluorometoxi o trifluorometilo; R a) es deuterio, halogeno, trialquilsililo C1-4, trifluorometoxi, trifluorometilo o hidrogeno; o b) es alcoxi C1-8 o alquilo C1-8; R2 a) es deuterio, halogeno, hidroxilo o hidrogeno; o b) es alquenilo C2-8, alquinilo C2-8, alcoxi C1-8, alcoxicarbonilo C1-4-alquilo C1-4, alquilo C1-8, alquilcarbonilo C0-4, arilalquilo C0-4, carboxialquilo C1-4, cicloalquilo C3-8 o heterociclilo insaturado-alquilo C0-4, radicales éstos que pueden estar sustituidos con 1-4 alcoxi C1-8, alcoxicarbonilo, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, arilo no sustituido o sustituido, aril-alcoxicarbonilo C0-4, ciano, halogeno, heterociclilo no sustituido o sustituido, hidroxilo, nitro, oxido, oxo, trialquilsililo C1-4, trifluorometoxi o trifluorometilo; R3 a) es deuterio, halogeno, hidroxilo, trifluorometoxi, trifluorometilo o hidrogeno; o b) es alcoxi C1-8 o alquilo C1- 8; R4 a) es deuterio, halogeno, trifluorometoxi, trifluorometilo o hidrogeno; o b) es alcoxi C1-8 o alquilo C1-8; n es un numero 0, 1 o 2; y las sales del mismo, preferentemente las sales adecuadas para uso farmacéutico de los mismos, donde si R2 es hidrogeno, R1 no es carbazolilo, fluorenilo ni naftilo; si R es hidrogeno y R2 es hidroxilo, R1 no es alcoxi C1-8 ni halobenzotiofen-2-ilo, bifenilo no sustituido o sustituido ni 4-bromofenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111907 | 2005-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056888A1 true AR056888A1 (es) | 2007-10-31 |
Family
ID=36284061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105413A AR056888A1 (es) | 2005-12-09 | 2006-12-07 | Derivados de heterociclil imidazol |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8008334B2 (es) |
| EP (1) | EP1957489A2 (es) |
| JP (1) | JP5258573B2 (es) |
| CN (2) | CN102115473A (es) |
| AR (1) | AR056888A1 (es) |
| BR (1) | BRPI0619536A2 (es) |
| CA (1) | CA2629137A1 (es) |
| IL (1) | IL191844A0 (es) |
| TW (1) | TW200804378A (es) |
| WO (1) | WO2007065942A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
| AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| PL2523731T3 (pl) | 2010-01-14 | 2019-04-30 | Novartis Ag | Zastosowanie środka modyfikującego hormon nadnerczy |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| CU24330B1 (es) | 2013-02-14 | 2018-03-13 | Novartis Ag | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) |
| CA2918074A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成ａｐｅｌｉｎ多肽之生物結合物 |
| KR20170103970A (ko) | 2015-01-23 | 2017-09-13 | 노파르티스 아게 | 개선된 반감기를 갖는 합성 아펠린 지방산 접합체 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| US20220024981A1 (en) | 2018-11-27 | 2022-01-27 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US5026712A (en) * | 1985-06-05 | 1991-06-25 | Schering Ag | Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents |
| JPH0670064B2 (ja) | 1986-12-08 | 1994-09-07 | 三井石油化学工業株式会社 | 二環性イミダゾ−ル誘導体 |
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| WO1997000257A1 (fr) * | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'imidazole fusionnes et composition medicinale les contenant |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| HU229408B1 (hu) | 2000-11-17 | 2013-12-30 | Takeda Pharmaceutical | Új imidazol-származékok és eljárás elõállításukra |
| AU2003201849A1 (en) * | 2002-01-10 | 2003-07-30 | Takeda Chemical Industries, Ltd. | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| WO2004075890A1 (ja) * | 2003-02-26 | 2004-09-10 | Takeda Pharmaceutical Company | 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法 |
| CA2519211A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Release control compositions |
| JP2008500999A (ja) * | 2004-05-28 | 2008-01-17 | シュペーデル・エクスペリメンタ・アーゲー | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
| CA2568165A1 (en) * | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| US20080076784A1 (en) * | 2004-05-28 | 2008-03-27 | Peter Herold | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors |
| WO2006093353A1 (ja) * | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200813071A (en) * | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
-
2006
- 2006-12-07 AR ARP060105413A patent/AR056888A1/es unknown
- 2006-12-07 TW TW095145550A patent/TW200804378A/zh unknown
- 2006-12-08 WO PCT/EP2006/069462 patent/WO2007065942A2/en active Application Filing
- 2006-12-08 BR BRPI0619536-9A patent/BRPI0619536A2/pt not_active IP Right Cessation
- 2006-12-08 US US12/086,193 patent/US8008334B2/en not_active Expired - Fee Related
- 2006-12-08 EP EP06830466A patent/EP1957489A2/en not_active Withdrawn
- 2006-12-08 CN CN201010539281XA patent/CN102115473A/zh active Pending
- 2006-12-08 CA CA002629137A patent/CA2629137A1/en not_active Abandoned
- 2006-12-08 CN CN200680045950XA patent/CN101326184B/zh not_active Expired - Fee Related
- 2006-12-08 JP JP2008543841A patent/JP5258573B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-29 IL IL191844A patent/IL191844A0/en unknown
-
2010
- 2010-10-08 US US12/900,779 patent/US8263615B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5258573B2 (ja) | 2013-08-07 |
| WO2007065942A3 (en) | 2007-07-26 |
| JP2009518365A (ja) | 2009-05-07 |
| CA2629137A1 (en) | 2007-06-14 |
| US20090197909A1 (en) | 2009-08-06 |
| BRPI0619536A2 (pt) | 2011-10-04 |
| CN101326184A (zh) | 2008-12-17 |
| US8263615B2 (en) | 2012-09-11 |
| US20110028512A1 (en) | 2011-02-03 |
| IL191844A0 (en) | 2008-12-29 |
| CN102115473A (zh) | 2011-07-06 |
| EP1957489A2 (en) | 2008-08-20 |
| US8008334B2 (en) | 2011-08-30 |
| TW200804378A (en) | 2008-01-16 |
| WO2007065942A2 (en) | 2007-06-14 |
| CN101326184B (zh) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR066691A1 (es) | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. | |
| AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| CO6190611A2 (es) | Derivados de espirocromanona sustituidos | |
| AR053739A1 (es) | Compuestos espiro condensados como inhibidores de la aldosterona sintasa | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR060084A1 (es) | Derivados de benzimidazol utiles como moduladores del complejo del receptor gaba-a | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| ECSP099394A (es) | Derivados de quinuclidinol como antogonistas de receptores muscarínicos | |
| UY30127A1 (es) | Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso. | |
| AR052312A1 (es) | 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |